araag2/HINT huggingface dataset:
Clinical trial NCT00055471 (phase 2, status: completed)
Conditions: prostatic neoplasms, metastases, neoplasm
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: zd4054 10 mg, zd4054 15 mg, zd4054 22.5 mg
SMILES: COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=C1)C1=NN=CO1, COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=C1)C1=NN=CO1, COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=C1)C1=NN=CO1
Eligibility criteria:

        Inclusion Criteria:

          -  Men 18 years & older

          -  Confirmed diagnosis of prostate cancer with bone metastases

        Exclusion Criteria:

          -  No more than 2 prior chemotherapy regimens

          -  No radiation, chemotherapy or bisphosphonates in the past 4 weeks
Clinical trial NCT00424814 (phase 2/phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: kaletra (lopinavir/ritonavir), kaletra (lopinavir/ritonavir) + combivir (zidovudine/lamivudine)
SMILES: CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria: Assessed between 20 and 24 months of pregnancy

          -  Pregnancy known before 24 weeks of gestation

          -  Documented HIV-1 infection without indication for ARV therapy

          -  CD4 count above or equal to 350 per mm3

          -  VL under 30 000 copies per ml

          -  Naïve for PI (except treatment during previous pregnancy)

          -  Informed consent signed

        Exclusion Criteria:

          -  HIV2 infection or HIV1 group O infection

          -  Any pathology related to pregnancy

          -  Contra-indication to study drugs

          -  Unstable hypertension or diabetes

          -  Known risk of premature delivery

          -  In case of previous treatment with a protease inhibitor : presence of resistance
             mutations on the HIV-1 protease gene by genotyping analysis (1 mutation among V32I et
             I47A, I50V V82A/F/S/T, I84V, L90 M or more than 3 mutations among L10 F/I/R/V,
             K20/M/R, L24I, L33F, M46I/L, F53L, I54M/L/T/V, L63P, A71L/V/T,)
Clinical trial NCT01069627 (phase 2, status: completed)
Conditions: malignant melanoma
ICD codes: C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, C43.10
Drugs: bevacizumab [avastin], fotemustine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)N=O
Eligibility criteria:

        Inclusion Criteria:

          -  cutaneous malignant melanoma;

          -  advanced, inoperable stage IV melanoma;

          -  measurable and/or evaluable sites of metastases.

        Exclusion Criteria:

          -  prior chemotherapy and/or IFN/IL2 based immunotherapy for metastatic disease;

          -  prior malignancies within past 5 years, with the exception of cured non-melanoma skin
             cancer, or in situ cancer of cervix;

          -  clinically significant cardiovascular disease;

          -  ongoing treatment with aspirin (>325mg/day) or other medications known to predispose
             to gastrointestinal ulceration.
Clinical trial NCT00193206 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, epirubicin, albumin-bound paclitaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Eligibility criteria:

        Inclusion Criteria:

        To be included in this study, you must meet the following criteria:

          -  Locally advanced/inflammatory adenocarcinoma of the breast

          -  18 years of age or older

          -  Normal heart function

          -  Able to perform activities of daily living with minimal assistance

          -  No prior chemotherapy for breast cancer

          -  Adequate bone marrow, liver and kidney function

          -  No evidence or history of significant cardiovascular abnormalities

          -  Sentinel node or axillary dissection

          -  Sign an informed consent form

        Exclusion Criteria:

        You cannot participate in this study if any of the following apply to you:

          -  Pregnant or breast feeding

          -  History of heart disease with congestive heart failure

          -  Heart attack within the previous 6 months

          -  Prior chemotherapy or hormone therapy for breast cancer

          -  History of active uncontrolled infection

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have.
Clinical trial NCT00191243 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  histologically verified diagnosis of breast carcinoma, at first diagnosis

          -  restricted previous adjuvant chemotherapy (completed >6 months prior the study)

          -  measurable and/or non-measurable disease

          -  previous radiotherapy is allowed if:terminated at least 10 days prior the sudy
             therapy, at least one target lesion for evaluation of tumor response has not been
             irradiated

          -  performance status 0-2 (WHO, Zubrod)

          -  adequate bone marrow reserve defined

          -  adequate liver / renal functions defined

        Exclusion Criteria:

          -  any prior systematic chemotherapy for metastatic breast cancer

          -  expected survival time less than 12 weeks

          -  past or current history of malignant neoplasm other than breast carcinoma

               -  except for cured non-melanoma skin cancer or curatively treated in situ carcinoma
                  of the cervix uteri

          -  known brain metastases/leptomeningeal involvement

          -  active uncontrolled infection

          -  symptomatic peripheral neuropathy > grade 2 according to NCI

          -  patients whose lesions are assessable only by radionuclide scan or patients with
             sclerotic bone lesions as the only site of disease

          -  concomitant illness that is contraindication to the use of corticosteroids

          -  other concomitant serious illness or medical condition, which may worsen due to the
             treatment
Clinical trial NCT00181532 (phase 2, status: completed)
Conditions: non small cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: celecoxib
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  histologically proven non-small cell lung cancer

          -  UICC stage II-III

          -  WHO performance status 0-2

          -  less than 10% weight loss the last 6 month

          -  in case of previous chemotherapy, radiotherapy may start after a minimum of 21 days
             after the last chemotherapy course

          -  reasonable lung function: FEV1>30% of the predicted value

          -  no recent(<3month) severe cardiac disease

          -  no active peptic ulcer disease

          -  normal serum bilirubin

          -  normal serum creatinin

          -  life expectancy more than 6 month

          -  measurable cancer

          -  willing and able to comply with the study prescriptions

          -  able to give written informed consent before patient registration/randomisation

          -  no previous radiotherapy to the chest

        Exclusion Criteria:

          -  not not small cell histology, e.g. mesothelioma, lymphoma

          -  mixed pathology, e.g. non small cell plus small cell cancer

          -  malignant pleural or pericardial effusion

          -  concurrent chemotherapy with radiation

          -  recent (<3month) myocardial infarction

          -  uncontrolled infectious disease

          -  distant metastases (stage IV)

          -  patients with active peptic ulceration or gastrointestinal bleeding in the last year

          -  patients with a past history of adverse reaction to NSAIDs

          -  renal disease

          -  chronic use of NSAIDs, COX-2 inhibitors or Aspirin in dosis >120mg/day.
Clinical trial NCT00186121 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: anastrozole (arimidex), goserelin (zoladex)
SMILES: CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
Eligibility criteria:

        INCLUSION CRITERIA

          -  Histologically-confirmed, bi-dimensionally measurable, recurrent or metastatic
             carcinoma of the breast that is progressive

          -  Premenopausal, defined as any of:

               1. Last menstrual period within 3 months, or

               2. Post-hysterectomy without bilateral oophorectomy and with follicle-stimulating
                  hormone (FSH) in the premenopausal range, or,

               3. If tamoxifen administered within the past 3 months, plasma estradiol must be in
                  the premenopausal range

          -  Either positive estrogen and/or progesterone receptor determination by
             Immunohistochemistry (IHC) or competitive binding assay on metastatic disease, or if
             not performed on their metastatic disease a positive result on their primary breast
             cancer specimen.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  Granulocytes > 1500/mm^3

          -  Platelets > 100,000/mm^3

          -  Serum glutamic oxaloacetic transaminase (SGOT) < 2.5 x upper limit of normal

          -  Total bilirubin < 1.5 mg/dL

          -  May have received irradiation to bony sites of disease for pain control or for
             prevention of fracture. The irradiated site(s) will NOT be evaluable for disease
             response.

          -  Must be using effective contraception or not be of childbearing potential

          -  Signed written informed consent

        INCLUSION CRITERIA

          -  Active, unresolved infection

          -  Active malignancy other than breast cancer, in situ carcinoma of the cervix, or
             non-melanomatous skin cancers in the past 5 years

          -  Prior treatment with an aromatase inhibitor or inactivator

          -  Prior treatment with an luteinizing hormone-releasing hormone (LH/RH)
             agonist/antagonist

          -  Adjuvant chemotherapy within 6 months of study entry.

          -  Received chemotherapy or hormonal therapy in the 3 weeks prior to enrollment

          -  Central nervous system metastasis

          -  Lymphangitic pulmonary metastasis

          -  Pregnant or lactating
Clinical trial NCT00546364 (phase 2, status: terminated)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ixabepilone, 40 mg/m^2 + capecitabine, 1000 mg/m^2, ixabepilone, 32 mg/m^2 + capecitabine, 1000 mg/m^2, docetaxel, 75 mg/m^2 + capecitabine, 1000 mg/m^2
SMILES: [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with metastatic breast cancer

          -  Measurable disease

          -  Up to 1 chemotherapy regimen is acceptable. Participants who have received paclitaxel
             in the neoadjuvant or adjuvant setting acceptable, only if the last dose of paclitaxel
             was received 12 months or less before the treatment. There is no timeframe for prior
             paclitaxel in the metastatic setting.

          -  Human epidermal growth factor receptor 2-positive participants allowed if they have
             progressed after receiving treatment with trastuzumab or lapatinib

          -  Eastern Cooperative Oncology Group Performance status of 0-1

          -  Age younger than 18 years

          -  Women of childbearing potential must be using an adequate method of contraception to
             avoid pregnancy throughout the study and for at least 4 weeks after the last dose of
             investigational products

        Exclusion Criteria:

          -  More than 1 chemotherapy regimen for the treatment of metastatic breast cancer

          -  Prior treatment with any epothilone, capecitabine, or docetaxel

          -  Prior radiation must not have included 30% or more of major bone marrow-containing
             areas (pelvis, lumbar spine). If prior radiation was less than 30%, a minimum interval
             of 2 weeks must be allowed between the last radiation treatment and administration of
             study medication. There must be at least 1 week between focal/palliative radiation and
             administration of study medication.

          -  Any current or previous history of brain and/or leptomeningeal metastases

          -  Neuropathy greater than Grade 2

          -  Any concurrent malignancy other than nonmelanoma skin cancer or carcinoma in situ of
             the cervix

          -  Uncontrolled diabetes mellitus

          -  Chronic hepatitis

          -  HIV-positive status

          -  Administration of trastuzumab, lapatinib, bevacizumab, or other systemic treatment for
             cancer must be discontinued 28 days prior to study medication. Hormonal anticancer
             agents must be discontinued at least 14 days prior to study medication. Hormonal
             replacement therapy is acceptable

          -  Biphosphonates for palliation of bone metastases allowed if initiated at least 7 days
             before study entry
Clinical trial NCT00413205 (phase 2, status: completed)
Conditions: emphysema
ICD codes: J43.1, J43.2, J43.8, J43.9, J98.2, J98.3, T79.7XXS
Drugs: placebo, rar gamma
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  patients of >44 years of age, with >10 pack-year smoking history;

          -  women not of child-bearing potential;

          -  ex-smokers (must have stopped smoking for >=12 months) with clinical diagnosis of
             emphysema;

          -  willing to be switched to optimal COPD therapy.

        Exclusion Criteria:

          -  off oral steroids >28 days prior to enrollment;

          -  >2 exacerbations of pulmonary symptoms requiring outpatient treatment, or >1
             exacerbation requiring hospitalization, within 12 months prior to screening;

          -  exposure to synthetic oral retinoids in past 12 months;

          -  history of allergy or sensitivity to retinoids.
Clinical trial NCT00263718 (phase 2, status: completed)
Conditions: psoriasis vulgaris
ICD codes: L40.0
Drugs: calcipotriol plus betamethasone dipropionate (leo 80185) gel
SMILES: O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Psoriasis vulgaris involving trunk and/or arms and/or legs amenable to treatment with
             a maximum of 100 g of topical medication per week

          -  An investigators' global assessment of disease severity of at least mild

        Exclusion Criteria:

          -  PUVA or Grenz ray therapy within 4 weeks prior to randomisation

          -  UVB therapy within 2 weeks prior to randomisation

          -  Systemic treatment with biological therapies, with a possible effect on psoriasis
             vulgaris within 6 months prior to randomisation

          -  Systemic treatment with all other therapies than biologicals, with a possible effect
             on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids,
             immunosuppressants) within 4 weeks prior to randomisation

          -  Any topical treatment of the trunk/limbs (except for emollients) within 2 weeks prior
             to randomisation

          -  Topical treatment for other relevant skin disorders (except WHO group I-II
             corticosteroids, tar, retinoid and dithranol on face, scalp, or flexures) within 2
             weeks prior to randomisation

          -  Planned initiation of, or changes to concomitant medication that could affect
             psoriasis vulgaris (e.g., beta blockers, anti-malaria drugs, lithium) during the study

          -  Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis
Clinical trial NCT01476475 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin glargine /lixisenatide fixed ratio combination, insulin glargine, metformin (background drug)
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion criteria:

          -  Participants with type 2 diabetes mellitus diagnosed for at least 1 year.

          -  Metformin treatment at a stable dose of at least 1.5 g/day for at least 3 months prior
             to screening.

        Exclusion criteria:

          -  Age < legal age of adulthood (18 years).

          -  Screening HbA1c <7% or >10%.

          -  Screening FPG >250 mg/dL (>13.9 mmol/L).

          -  Pregnancy or lactation, women of childbearing potential with no effective
             contraceptive method.

          -  Type 1 diabetes mellitus.

          -  Treatment with glucose-lowering agent(s) other than metformin in a period of 3 months
             prior to screening.

          -  Use of insulin within the last 6 months.

          -  Previous use of insulin, except for episode(s) of short-term treatment (≤15
             consecutive days) due to intercurrent illness.

          -  Amylase and/or lipase >3 times the upper limit of the normal laboratory range (ULN) at
             screening.

          -  Calcitonin ≥20 pg/ml (5.9 pmol/l) at screening.

          -  Alanine Transferase (ALT) >3 ULN at screening.

          -  History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy.

          -  Personal or immediate family history of medullary thyroid cancer (MTC) or genetic
             conditions that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes).

          -  Uncontrolled or inadequately controlled hypertension at the time of screening with a
             resting supine systolic or diastolic blood pressure >180 mmHg or >110 mmHg,
             respectively.

          -  Within the last 6 months prior to screening: history of heart failure requiring
             hospitalization, myocardial infarction, or stroke. Planned coronary, carotid or
             peripheral artery revascularisation procedures.

          -  Body Mass Index (BMI) ≤20 or >40 kg/m^2.

          -  Any previous treatment with lixisenatide

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT00565812 (phase 2, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: sd-6010, sd-6010, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects aged >= 40 years with a BMI >= 25 and <= 40 kg/m2

          -  In the past, has been diagnosed with knee OA

          -  Radiographic evidence of OA in the study knee

        Exclusion Criteria:

          -  A diagnosis of any other rheumatic disease

          -  Current conditions in the study knee that would confound efficacy

          -  Selected, traditional clinical safety and laboratory parameters
Clinical trial NCT01167257 (phase 2, status: completed)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: liposome encapsulated botulinum toxin a, normal saline instillation
SMILES: N[C@@H](CO)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Adults with age of 20 years old or above

          2. Patients with symptoms of urgency frequency and/or urge incontinence and a urgency
             severity scale (USS) of at least 2, with or without urodynamically proven detrusor
             overactivity (DO) (defined by the International Continence Society (ICS)
             recommendation as: spontaneous detrusor contraction occurring during bladder filling
             phase or occurring before uninhibited detrusor contraction voiding at bladder capacity
             in the urodynamic study)

          3. Free of active urinary tract infection

          4. Free of bladder outlet obstruction on enrollment

          5. Free of overt neurogenic bladder dysfunction

          6. Having been treated with antimuscarinic agents for at least 4 weeks without effect or
             with intolerable adverse effects

          7. Patient has not been treated with bladder surgery for OAB, such as enterocystoplasty,
             that might affect the therapeutic effect of test drug

          8. Patient can record voiding diary for the urinary frequency and urgency

          9. Patient or his/her legally acceptable representative has signed the written informed
             consent form

        Exclusion Criteria:

          1. Use of antimuscarinic agent and effective in treatment of lower urinary tract symptoms

          2. Patients with severe cardiopulmonary disease and such as congestive heart failure,
             arrhythmia, poorly controlled hypertension, not able to receive regular follow-up

          3. Patients with bladder outlet obstruction on enrollment

          4. Patients with postvoid residual >150 mL

          5. Patients with uncontrolled confirmed diagnosis of acute urinary tract infection

          6. Patients have laboratory abnormalities at screening including:

             Alanine aminotransferase (ALT) >3 x upper limit of normal range Aspartate
             aminotransferase (AST) >3 x upper limit of normal range Patients have abnormal serum
             creatinine level >2 x upper limit of normal range

          7. Patients with any contraindication to be urethral catheterization during treatment

          8. Female patients who is pregnant, lactating, or with child-bearing potential without
             contraception.

          9. Myasthenia gravis, Eaton Lambert syndrome.

         10. Patients with any other serious disease considered by the investigator not suitable
             for general anesthesia or in the condition to enter the trial

         11. Patients participated investigational drug trial within 1 month before entering this
             study